Novavax (NVAX) Tops Q1 EPS by 18c; offers guidance

Novavax (NASDAQ: NVAX) reported Q1 EPS of ($0.06), $0.18 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $139.51 million versus the consensus estimate of $79.31 million.

GUIDANCE:

Novavax sees FY2026 revenue of $230-270 million, versus the consensus of $394.3 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.

You May Also Be Interested In

• MongoDB stock drops 15% as CEO Desai resigns for Meta
• MaxLinear launches Puma 9 DOCSIS chip with Wi-Fi 8 and AI support
• JPMorgan Reiterates Overweight Rating on Take-Two Interactive (TTWO) Amid Cautious Sentiment